3,295 reports of this reaction
1.4% of all SILDENAFIL CITRATE reports
#17 most reported adverse reaction
PULMONARY ARTERIAL HYPERTENSION is the #17 most commonly reported adverse reaction for SILDENAFIL CITRATE, manufactured by Viatris Specialty LLC. There are 3,295 FDA adverse event reports linking SILDENAFIL CITRATE to PULMONARY ARTERIAL HYPERTENSION. This represents approximately 1.4% of all 242,442 adverse event reports for this drug.
SILDENAFIL CITRATE has an overall safety score of 85 out of 100. Patients taking SILDENAFIL CITRATE who experience pulmonary arterial hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY ARTERIAL HYPERTENSION is a less commonly reported adverse event for SILDENAFIL CITRATE, but still significant enough to appear in the safety profile.
In addition to pulmonary arterial hypertension, the following adverse reactions have been reported for SILDENAFIL CITRATE:
The following drugs have also been linked to pulmonary arterial hypertension in FDA adverse event reports:
PULMONARY ARTERIAL HYPERTENSION has been reported as an adverse event in 3,295 FDA reports for SILDENAFIL CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY ARTERIAL HYPERTENSION accounts for approximately 1.4% of all adverse event reports for SILDENAFIL CITRATE, making it a notable side effect.
If you experience pulmonary arterial hypertension while taking SILDENAFIL CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.